Bottom line
PHSZX vs QAAGZX: the short answer
PHSZX (PGIM Jennison Health Sciences Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) are both mutual funds.
But QAAGZX is far broader, holding 277 positions to 55 for PHSZX, so beyond the top names it adds exposure PHSZX doesn't have.
QAAGZX is cheaper at 0.86% vs 0.88% — a difference of $2.00 a year per $10,000 invested.
Over five years, PHSZX returned +7.0% a year vs +4.1% for QAAGZX (reporting dates differ).
Updated Nov 19, 2026
PHSZX vs QAAGZX side by side
| PHSZX | QAAGZX | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | PGIM (Prudential) | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.88% | 0.86% |
| Annual cost per $10k | $88 | $86 |
| 10-yr cost on $10k (prospectus) | $1,084 | $1,061 |
| Max front load | 0% | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +19.6% | +18.1% |
| 5-yr return (annualized) | +7.0% | +4.1% |
| 10-yr return (annualized) | +9.8% | +9.0% |
| Best quarter | +29.7% | +23.4% |
| Worst quarter | −20.5% | −15.8% |
| Net assets (fund) | $1.4B | $751.7M |
| Number of holdings | 55 | 277 |
| Portfolio turnover | 81% | 65% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PHSZX | QAAGZX | Difference |
|---|---|---|---|
| 2024 | +19.6% | +1.7% | +17.9% |
| 2023 | +8.8% | +3.0% | +5.9% |
| 2022 | +12.6% | −12.5% | +25.1% |
| 2021 | −10.1% | +13.1% | −23.2% |
| 2020 | +6.3% | +29.6% | −23.3% |
| 2019 | +41.7% | +29.0% | +12.7% |
| 2018 | +18.6% | +1.1% | +17.5% |
| 2017 | −3.4% | +27.6% | −31.0% |
| 2016 | +31.4% | −10.5% | +41.9% |
Source: Fund prospectus bar charts
Holdings overlap
9 of PHSZX's top 25 holdings also appear in QAAGZX's top 25.
| Holding | PHSZX | QAAGZX |
|---|---|---|
| Eli Lilly & Company | 17.35% | 14.06% |
| Merck & Company Inc | 6.06% | 4.00% |
| Unitedhealth Group Inc | 5.87% | 5.88% |
| Thermo Fisher Scientific Inc | 4.56% | 2.53% |
| Vertex Pharmaceuticals Inc | 3.37% | 2.26% |
| Danaher Corp | 3.28% | 1.44% |
| Intuitive Surgical Inc | 3.07% | 1.89% |
| Cvs Health Corp | 2.52% | 0.93% |
| Stryker Corp | 2.16% | 1.78% |
Source: SEC Form N-PORT
PHSZX top 10
- Eli Lilly & Company — 17.35%
- Merck & Company Inc — 6.06%
- Unitedhealth Group Inc — 5.87%
- Thermo Fisher Scientific Inc — 4.56%
- Argenx Se — 3.55%
- Vertex Pharmaceuticals Inc — 3.37%
- Danaher Corp — 3.28%
- Intuitive Surgical Inc — 3.07%
- Lonza Group Ag — 3.02%
- Cvs Health Corp — 2.52%
QAAGZX top 10
- Eli Lilly & Co — 14.06%
- Johnson & Johnson — 6.64%
- Unitedhealth Group Inc — 5.88%
- Abbvie Inc — 5.12%
- Merck & Co. Inc. — 4.00%
- Gilead Sciences Inc — 2.79%
- Thermo Fisher Scientific Inc — 2.53%
- Vertex Pharmaceuticals Inc — 2.26%
- Bristol-myers Squibb Co — 2.12%
- Abbott Laboratories — 1.91%
FAQ
What is the difference between PHSZX and QAAGZX?
Which is cheaper, PHSZX or QAAGZX?
Should I own both PHSZX and QAAGZX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.